Access to groundbreaking medicines is meaningless without real patient access.
In our journey spanning over 50 years, we've advanced our science and manufacturing to supply insulin to nearly 30 million people.
Yet, the urgency for patients with type two diabetes and obesity is palpablethey can't afford to wait another half-century.
That's why, since early last year, I've committed over $30 billion to significantly boost our manufacturing capacity.
How do you think this investment will impact patient access to life-saving treatments?
Lars Fruergaard Jrgensen, President and Chief Executive Officer of Novo Nordisk, based in Bagsvrd, Denmark, testified before the Senate HELP Committee to address the question: Why is Novo Nordisk charging Americans with diabetes and obesity outrageously high prices for Ozempic and Wegovy?
